For Novartis, No Relax’in On Serelaxin: More Trials Likely
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis released mixed Phase III data on its heart failure candidate at the American Heart Association Scientific Sessions, showing the drug reduced symptoms of acute heart failure but failed to demonstrate an improvement on a second endpoint, cardiovascular death and hospital stays at 60 days.